Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2022-03-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司独立董事关于第八届董事会第十八次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions related to agenda items for the 18th meeting of the 8th Board of Directors. It references compliance with regulations and company bylaws, and approval of proposals to be submitted to the board meeting. There is no financial data, no audit report itself, no full annual or interim report, and no announcement of voting results. The document is a governance-related statement concerning board meeting matters and independent directors' opinions. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters. The document is short and does not contain financial statements or audit results, so it is not an audit report or annual report. Therefore, the classification is MANG with high confidence.
2022-03-28 Chinese
金陵药业关于公司及子公司使用闲置资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the company's and its subsidiaries' use of idle funds to purchase low-risk financial products. It details the board meeting resolution, investment purpose, amount, types of products, risk analysis, risk control measures, and opinions from independent directors and the supervisory board. The document is focused on informing shareholders and the public about the company's financial management activities related to idle funds, specifically the purchase of wealth management products. It does not contain financial statements, earnings data, or detailed financial performance analysis. It is not a full financial report, audit report, or earnings release. It is also not a regulatory filing or certification. The document is a formal announcement about capital usage and investment activities, which fits best under the category of Capital/Financing Update (CAP). The document length is 3289 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2022-03-28 Chinese
金陵药业关于2021年度日常关联交易执行情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the execution of daily related party transactions for the fiscal year 2021 by Jinling Pharmaceutical Co., Ltd. It includes detailed descriptions of related party transactions, their amounts, related parties, pricing policies, and independent directors' opinions. The document references the Shenzhen Stock Exchange Listing Rules and company bylaws, and it is dated March 25, 2022. It is not a full annual report or financial statement but a regulatory announcement about related party transactions, which is a common regulatory disclosure. The document is over 11,000 characters, indicating it is substantive and not a brief notice. It does not contain full financial statements or comprehensive management discussion but focuses on related party transaction disclosures. This type of document fits best under Regulatory Filings (RNS) as it is a compliance disclosure related to corporate governance and regulatory requirements rather than a full financial report or other specific category.
2022-03-28 Chinese
金陵药业关于公司2021年度核销资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the write-off of assets for the fiscal year 2021. It details the amounts and reasons for write-offs of various asset categories such as accounts receivable, inventory, fixed assets, and biological assets. The announcement includes statements from the board of directors, supervisory board, and independent directors confirming the appropriateness and compliance of the write-offs with accounting standards. It also references an audit report by an accounting firm. The document is relatively short (2633 characters) and serves as a formal disclosure of a specific corporate action (asset write-off) rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed audit opinions typical of an Annual Report (10-K) or Audit Report (AR). Instead, it is a regulatory announcement about a specific accounting event. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2022-03-28 Chinese
证券投资专项说明
Regulatory Filings Classification · 90% confidence The document is a special explanation by the board of directors regarding the company's securities investment situation for the year 2021. It includes detailed financial data on securities held, investment income, fair value changes, and internal control measures related to securities investment. The document is relatively short (1601 characters) and focuses on a specific aspect of financial activity rather than a full annual or quarterly report. It is not an announcement of a report publication but a standalone explanation. This type of document fits best under 'Regulatory Filings' (RNS) as it is a regulatory disclosure about securities investment details without being a full financial report or other specific filing type.
2022-03-28 Chinese
独立董事对担保等事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various proposals and matters discussed at the 18th meeting of the 8th board of directors of Jinling Pharmaceutical Co., Ltd. It includes opinions on related party transactions, profit distribution plans, internal control self-evaluation, asset impairment, asset write-offs, securities investment, remuneration of directors and senior management, appointment of auditors, use of idle funds, and nomination of a non-independent director. The document references compliance with laws and regulations and is a formal opinion report rather than a full financial report or announcement. It is not an annual report, audit report, earnings release, or any other financial statement. It is a governance-related document providing independent directors' opinions on board matters and proposals to be submitted to the shareholders' meeting. Therefore, it fits best under Board/Management Information (MANG). The document length is 3033 characters, which is relatively short but contains substantive content related to board decisions and independent directors' opinions, not just an announcement or certification. Hence, the classification is MANG with high confidence.
2022-03-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.